A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0305892 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Tufail M Malik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, United States of America. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Pneumococcal Infections, Streptococcus pneumoniae, Vaccination. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.
Abstract (Originalsprache)
Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with each vaccine covering a variable number of the more than 100 known serotypes. Due to the high effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured compartmental model was created that reproduced historical carriage transmission dynamics in the United States and was used to evaluate the population-level impact of new vaccine introductions into the pediatric population. The model incorporates co-colonization and serotype competition, which drives replacement of the vaccine types by the non-vaccine types. The model was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data from the United States. Vaccine-specific coverage and effectiveness were integrated in accordance with the recommended timelines for each age group. Demographic parameters were derived from US-population-specific databases, while population mixing patterns were informed by US-specific published literature on age-group based mixing matrices. The calibrated model was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, United States of America.
- Wolfram Research, Inc., Champaign, Illinois, United States of America.
ORCID-Profile: Tufail M Malik, Kevin M Bakker, Robert B Nachbar
Förderung
- Merck
Zitieren
APA
Malik, T. M., Bakker, K. M., Oidtman, R. J., Sharomi, O., Meleleo, G., Nachbar, R. B., & Elbasha, E. H. (2025). A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States. PLOS ONE. https://doi.org/10.1371/journal.pone.0305892
Vancouver
Malik TM, Bakker KM, Oidtman RJ, Sharomi O, Meleleo G, Nachbar RB, et al. A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States. PLOS ONE. 2025. doi:10.1371/journal.pone.0305892
BibTeX
@article{Malik2025,
author = {Malik, Tufail M and Bakker, Kevin M and Oidtman, Rachel J and Sharomi, Oluwaseun and Meleleo, Giulio and Nachbar, Robert B and Elbasha, Elamin H},
title = {A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0305892}
}
EUVIMED